Revenue FY2025
$67.0M
Net Income
$(279.0M)
EPS (Basic)
$-3.18
Net Margin
-412.9%
ROE
-160.0%
Total Equity
$174.0M
Shares Out
89M
Kura Oncology, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2007–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 4 funds in our universe
Insider Transactions
Reading stored insider transactions…